Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make

Merck CEO Rob Davis expects the current six-week turnaround for its personalized cancer vaccine with Moderna to shorten over time, while prioritizing supply and launch readiness; the companies reported positive initial late-stage trial data in melanoma in August. Merck also opened a 120,000-square-foot R&D facility with automated systems and AI capabilities, as it prepares for Keytruda’s core U.S. compound patent expiration in December 2028 and says it has committed $65 billion to external acquisitions and licensing over five years. A Dutch court has blocked sales, stocking and manufacturing of subcutaneous Keytruda in eight European countries following Halozyme’s patent suit; Merck plans to appeal, and patients can still receive the original formulation in Europe.

Analysis

The market-relevant question is not whether the personalized vaccine can be made faster, but whether Merck and Moderna can make turnaround time predictable across sites without compromising quality. A six-week patient-specific workflow is a potential throughput constraint: shortening it may expand the addressable patient pool, but it does not establish commercial-scale capacity, reimbursement, or repeatable outcomes. Until those are demonstrated, treat the CEO’s confidence as an operating aspiration, not a forecastable revenue catalyst. The new research facility is similarly an input; productivity gains need to show up in development timelines or pipeline output before they warrant a valuation premium.

For Merck, the vaccine is strategically useful but unlikely to offset Keytruda exclusivity exposure on a near-term horizon. The larger near-term swing factor is whether subcutaneous conversion preserves franchise economics; Halozyme’s litigation raises uncertainty around that pathway, while continued availability of IV treatment limits the direct downside from an adverse ruling. The dispute is therefore more about the size and durability of the transition opportunity than an immediate loss of the underlying franchise.

Over days, the interview and facility opening are weak standalone catalysts. Over 1–3 months, watch trial updates, launch execution, and material court or appeal developments. Over 6–18 months, the thesis depends on reproducible vaccine manufacturing, broader-tumor evidence, and measurable pipeline productivity. Contrarian view: investors may over-credit manufacturing optimism while underweighting that personalized production and clinical validation are distinct bottlenecks. No high-conviction trade follows from this article alone.

Key Decisions for Investors

• MRK: Do not add on the interview or facility announcement alone. Reassess on evidence of pipeline productivity and on subcutaneous Keytruda uptake or legal developments; falsify the franchise-transition thesis if guidance or reported performance shows meaningful erosion without offsetting launches.
• MRNA: Keep the personalized-vaccine opportunity on a catalyst watchlist, not in near-term earnings estimates. Look for quantified turnaround-time, manufacturing success-rate, trial, and commercial-partner economics before treating faster production as a revenue driver.
• HALO: Treat the litigation as a binary risk to the subcutaneous-conversion opportunity, not to Merck’s entire IV franchise. Avoid sizing a directional position without tracking court/appeal milestones and the geographic scope of any restrictions.
• No event-driven trade is warranted from these comments alone. Revisit only if clinical or manufacturing evidence changes expected patient throughput, or a legal ruling materially changes the addressable subcutaneous market.